ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction. Commentary

Robert O. Bonow, MD, FACC, FAHA, Chair; Susan J. Bennett, DNSC, RN, FAAN, FAHA; Gregory Burke, MD, MS, FAHA; Kim A. Eagle, MD, FACC, FAHA, Chair*; Harlan M. Krumholz, MD, FACC, FAHA†; Costas T. Lambrew, MD, MACC†; Jane Linderbaum, NP; Frederick A. Masoudi, MD, FACC, FAHA; Sharon-Lise T. Normand, PhD, MSC, FACC†; Ileana L. Piña, MD, FACC; Martha J. Radford, MD, FACC, FAHA; John S. Rumsfeld, MD, PhD, FACC; James L. Ritchie, MD, FACC†; John A. Spertus, MD, MPH, FACC†

[1]  Harlan M Krumholz,et al.  ACC/AHA clinical performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-El , 2006, Journal of the American College of Cardiology.

[2]  S. Normand,et al.  American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. , 2005, Journal of the American College of Cardiology.

[3]  L. Wilkins ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .

[4]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[5]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[6]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[7]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[8]  A. Maggioni,et al.  Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data , 2001, Heart.

[9]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[10]  L. Køber,et al.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction , 1999, The Lancet.

[11]  E. Braunwald Acute myocardial infarction--the value of being prepared. , 1996, The New England journal of medicine.

[12]  Raymond C. Schneider,et al.  ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction , 1995, The Lancet.

[13]  G. Lamas,et al.  Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.

[14]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[15]  L. Køber,et al.  Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. , 1999, Lancet.

[16]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. , 1995, The New England journal of medicine.